Silodosin
| 證據等級: L5 | 預測適應症: 6 個 |
目錄
- Silodosin
- Silodosin: From Benign Prostatic Hyperplasia to Ambras Type Hypertrichosis Universalis Congenita
Using no additional skill — this is a direct content-generation task against a fully specified template; proceeding straight to the report.
Silodosin: From Benign Prostatic Hyperplasia to Ambras Type Hypertrichosis Universalis Congenita
One-Sentence Summary
Silodosin is a highly selective α1A-adrenergic receptor antagonist, pharmacologically used for benign prostatic hyperplasia (BPH)/lower urinary tract symptoms. The TxGNN model's top-ranked prediction is Ambras type hypertrichosis universalis congenita (score 99.99%), but this prediction is currently supported by zero clinical trials and zero publications, with no known mechanistic pathway connecting α1A blockade to hair follicle biology.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Benign prostatic hyperplasia / lower urinary tract symptoms (inferred from drug class and repurposing rationale text; not present in evidence pack — original_indications is empty) |
| Predicted New Indication | Ambras type hypertrichosis universalis congenita |
| TxGNN Prediction Score | 99.99% (model rank 168) |
| Evidence Level | L5 |
| Germany Market Status | Not marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not available (original_moa: [Data Gap]). Based on the drug class and the rationale field embedded in the prediction, silodosin is a highly selective α1A-adrenergic receptor antagonist acting primarily on prostatic and lower urinary tract smooth muscle, and it is presumed to be used for BPH.
Ambras type hypertrichosis universalis congenita is a rare congenital disorder linked to chromosomal rearrangements and hair follicle developmental genes. There is no established biological pathway connecting peripheral α1A-receptor blockade to hair follicle growth regulation — drug-induced hypertrichosis is more commonly associated with potassium-channel openers (e.g., minoxidil), not α-adrenergic antagonism. The evidence pack's own rationale field explicitly flags this as a high-score/no-mechanism case, meaning the TxGNN association likely reflects embedding-space noise rather than a biologically grounded signal.
All five other candidates in this evidence pack (hypertrichosis, periodontal malformation syndrome, Dandy-Walker malformation, hair shaft abnormality, familial trichomegaly) share the same pattern: very high TxGNN scores paired with no clinical trial evidence and, where literature exists, matched publications unrelated to the drug (see below).
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
(Note: rank 3 candidate "malformation syndrome with odontal/periodontal component" returned 20 periodontitis-related publications, but none mention silodosin or α1-antagonists — these are considered irrelevant co-occurrence matches, not supporting evidence for the top prediction.)
Germany Market Information
Silodosin currently has no market authorization records in Germany (total_licenses: 0, licenses: []). This drug is not marketed in the German dataset covered by this evidence pack.
Safety Considerations
Please refer to the package insert for safety information.
(Note: safety.key_warnings and safety.contraindications are both flagged as data gaps in this evidence pack — item DG001, severity "Blocking," specifically blocks S1 safety pre-assessment pending TFDA label retrieval.)
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction carries a high TxGNN score but zero clinical or literature support, no plausible mechanistic link, and the drug is not currently marketed in Germany. Combined with a Blocking-severity safety data gap (DG001) and missing MOA data (DG002), this candidate does not meet the minimum bar to proceed to safety pre-assessment (S1).
To proceed, the following is needed:
- TFDA label (warnings/contraindications) retrieval to resolve DG001 (Blocking)
- Confirmed MOA from DrugBank to resolve DG002 and enable mechanistic evaluation
- Confirmed original indication and Germany/Taiwan market status (currently absent from source data)
- Any preclinical or case-level evidence linking α1-adrenergic antagonism to hair follicle or congenital hypertrichosis pathways — none currently exists
- If no such evidence emerges, this candidate should be deprioritized in favor of other TxGNN predictions with actual trial/literature backing
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.